SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL ...

Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated and full approval – – KOMET-017-NIC trial of ...
Targeted Oncology

Regulatory Milestones May Hasten Novel Immunotherapy for AML

The US FDA has granted fast track designation to CER-1236, an investigational cellular immunotherapy, for the treatment of acute myeloid leukemia (AML). 1 This designation is in addition to the ...
American Banker

Fincen seeks comment on costs of nonbank AML compliance

The Treasury Department's Financial Crimes Enforcement Network is seeking public comment on a survey of anti-money laundering ...
FinanceFeeds

Sumsub Unveils Free AML Training Course For 2025

Sumsub, a global full-cycle verification platform, has launched its AML Fundamentals course, a free training program aimed at ...
Nasdaq

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...